Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics
Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support
Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions
Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model
